Brian Fabian Saway

Dr. Brian Fabian Saway

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Neurotherapeutics
Verified
Journal Article
Open access
BSBrian Fabian Saway
Brian Fabian Saway
CPCharles Palmer
Charles Palmer
CHChristopher Hughes
Christopher Hughes
MTMatthew Triano
Matthew Triano
RSRishishankar E. Suresh
Rishishankar E. Suresh
NRNathan C. Rowland
Nathan C. Rowland
Stroke is one of the most common and debilitating neurological conditions worldwide. Those who survive experience motor, sensory, speech, vision, and/or cognitive deficits that severely limit remaining quality of life. While rehabilitation programs can help improve patients' symptoms, recovery is often limited, and patients frequently continue to experience impairments in functional status. In this review, invasive neuromodulation techniques to augment the effects of conventional rehabilitation methods are described, including vagus nerve stimulation (VNS), deep brain stimulation (DBS) and brain-computer interfaces (BCIs). In addition, the evidence base for each of these techniques, pivotal trials, and future directions are explored. Finally, emerging technologies such as functional near-infrared spectroscopy (fNIRS) and the shift to artificial intelligence-enabled implants and wearables are examined. While the field of implantable devices for chronic stroke recovery is still in a nascent stage, the data reviewed are suggestive of immense potential for reducing the impact and impairment from this globally prevalent disorder.

10 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
TLThomas Larrew
Thomas Larrew
BSBrian Fabian Saway
Brian Fabian Saway
SLStephen R. Lowe
Stephen R. Lowe
AOAdriana Olar
Adriana Olar
Ependymoma is a biologically diverse tumor wherein molecular classification has superseded traditional histological grading based on its superior ability to characterize behavior, prognosis, and possible targeted therapies. The current, updated molecular classification of ependymoma consists of ten distinct subgroups spread evenly among the spinal, infratentorial, and supratentorial compartments, each with its own distinct clinical and molecular characteristics. In this review, the history, histopathology, standard of care, prognosis, oncogenic drivers, and hypothesized molecular targets for all subgroups of ependymoma are explored. This review emphasizes that despite the varied behavior of the ependymoma subgroups, it remains clear that research must be performed to further elucidate molecular targets for these tumors. Although not all ependymoma subgroups are oncologically aggressive, development of targeted therapies is essential, particularly for cases where surgical resection is not an option without causing significant morbidity. The development of molecular therapies must rely on building upon our current understanding of ependymoma oncogenesis, as well as cultivating transfer of knowledge based on malignancies with similar genomic alterations.

19 December 2017 in Journal of Cell Biology
Verified
Journal Article
Open access
RARebecca C. Adikes
Rebecca C. Adikes
RHRyan A. Hallett
Ryan A. Hallett
BSBrian Fabian Saway
Brian Fabian Saway
BKBrian Kuhlman
Brian Kuhlman
KSKevin C. Slep
Kevin C. Slep
We developed a novel optogenetic tool, SxIP–improved light-inducible dimer (iLID), to facilitate the reversible recruitment of factors to microtubule (MT) plus ends in an end-binding protein–dependent manner using blue light. We show that SxIP-iLID can track MT plus ends and recruit tgRFP-SspB upon blue light activation. We used this system to investigate the effects of cross-linking MT plus ends and F-actin in Drosophila melanogaster S2 cells to gain insight into spectraplakin function and mechanism. We show that SxIP-iLID can be used to temporally recruit an F-actin binding domain to MT plus ends and cross-link the MT and F-actin networks. Cross-linking decreases MT growth velocities and generates a peripheral MT exclusion zone. SxIP-iLID facilitates the general recruitment of specific factors to MT plus ends with temporal control enabling researchers to systematically regulate MT plus end dynamics and probe MT plus end function in many biological processes. Graphical Abstract

1 September 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
BSBrian Fabian Saway
Brian Fabian Saway
LSLaurie W Seidel
Laurie W Seidel
FDFrancis C Dane
Francis C Dane
TWTerri Wattsman
Terri Wattsman

1 July 2023 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
BSBrian Fabian Saway
Brian Fabian Saway
WRWarren Roth
Warren Roth
CSCraig D. Salvador
Craig D. Salvador
MEMuhammed Amir Essibayi
Muhammed Amir Essibayi
GPGuilherme B. F. Porto
Guilherme B. F. Porto
ASAlejandro Spiotta
Alejandro Spiotta
OBJECTIVE: Middle meningeal artery (MMA) embolization and the Subdural Evacuation Port System (SEPS) are minimally invasive treatment paradigms for chronic subdural hematoma (cSDH). Although SEPS offers acute decompression of local mass effect from a cSDH, MMA embolization has been shown to reduce the rate of cSDH recurrence. In combination, these procedures present a potentially safer strategy to a challenging pathology. The authors present a multi-institutional retrospective case series that assessed the safety, efficacy, and complications of SEPS and MMA embolization for cSDH. METHODS: A retrospective review was performed of patients who underwent SEPS placement and MMA embolization for cSDH between 2018 and 2021 at three institutions. RESULTS: One hundred patients with 136 cSDHs and a median age of 73 years underwent both SEPS placement and MMA embolization. Initial Glasgow Coma Scale scores were between 14 and 15 in 81% of patients and between 9 and 13 in 14%. The median initial midline shift (MLS) was 7 mm, with subdural hematoma (SDH) in the left hemisphere (lh) in 30% of patients, right hemisphere (rh) in 34%, and bilateral hemispheres in 36%. Follow-up was available for 86 patients: 93.4% demonstrated decreased MLS, and all patients with lhSDH and rhSDH demonstrated progressive decrease in SDH size. The overall complication rate was 4%, including 1 case of facial palsy and 3 cases of iatrogenic acute SDH. Two subjects (2%) required craniotomy for hematoma evacuation. The rate of good functional outcomes, with modified Rankin Scale (mRS) score < 2, was 89% on final follow-up and the overall mortality rate was 2%. A good mRS score on admission was associated with increased odds of functional improvement at follow-up (p < 0.001). CONCLUSIONS: SEPS placement with MMA embolization for cSDH can be done safely and effectively reduces cSDH size with minimal perioperative morbidity.

1 March 2020 in World Neurosurgery
Verified
Journal Article
Closed access
LDLisette Dominguez
Lisette Dominguez
BSBrian Fabian Saway
Brian Fabian Saway
MBMichael J. Benko
Michael J. Benko
EGEvin Guilliams
Evin Guilliams
EMEric A. Marvin
Eric A. Marvin
JEJohn J. Entwistle
John J. Entwistle